TSTyler Stevens

Tyler Stevens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tyler Stevens has a total of 133 co-authors. Here are the top co-authors by number of shared publications:

  • Rocio Lopez

    Section of Biostatistics and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH, USA

    9 shared publications
  • John J. Vargo

    Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA

    8 shared publications
  • Mansour A. Parsi

    Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio

    6 shared publications
  • Amit Bhatt

    Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH

    5 shared publications
  • Amit Bhatt

    Department of Gastroenterology, Digestive Disease Institute, The Cleveland Clinic, Cleveland, OH, USA

    3 shared publications
  • Georgios I. Papachristou

    Department of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA

    3 shared publications

Latest Publications

  • Open Access

    Utility of Hydro-Computed Tomography in Diagnosing Surgical Clip Migration into the Gastric Wall Post-splenectomy

    by Ridhima Kaul, Arjun Chatterjee, Andrei Purysko, Tyler Stevens, Hassan Siddiki, Amit Bhatt, Kyungran Justina Cho

  • Open Access

    Clinical Evaluation of Patients with Elevated Serum Lipase

    by Arjun Chatterjee, Renan Prado, Hassan Siddiki, Tyler Stevens


  • Mortality Trends, Outcomes, and Predictors of Portal Vein Thrombosis in Acute Pancreatitis Patients: A Propensity-Matched National Study

    by Rajat Garg, Abdul Mohammed, Amandeep Singh, Hassan Siddiki, Amit Bhatt, Madhusudhan R. Sanaka, Sunguk Jang, C. Roberto Simons-Linares, Tyler Stevens, John Vargo, et al.

    Background Portal vein thrombosis (PVT) is a rare complication of acute pancreatitis (AP) and might be associated with worse outcomes. We aimed to study trends, outcomes, and predictors of PVT in AP patients. Methods The National Inpatient Sample database was utilized to identify the adult patients (≥ 18 years) with primary diagnosis of AP from 2004 to 2013 using International Classification of Disease, Ninth Revision. Patients with and without PVT were entered into propensity matching model based on baseline variables. Outcomes were compared between both groups and predictors of PVT in AP were identified. Results Among the total of 2,389,337 AP cases, 7046 (0.3%) had associated PVT. The overall mortality of AP decreased throughout the study period (p trend ≤ 0.0001), whereas mortality of AP with PVT remained stable (1–5.7%, p trend = 0.3). After propensity matching, AP patients with PVT patients had significantly higher in-hospital mortality (3.3% vs. 1.2%), AKI (13.4% vs. 7.7%), shock (6.9% vs. 2.5%), and need for mechanical ventilation (9.2% vs. 2.5%) along with mean higher cost of hospitalization and length of stay (p < 0.001 for all). Lower age (Odd ratio [OR] 0.99), female (OR 0.75), and gallstone pancreatitis (OR 0.79) were negative predictors, whereas alcoholic pancreatitis (OR 1.51), cirrhosis (OR 2.19), CCI > 2 (OR 1.81), and chronic pancreatitis (OR 2.28) were positive predictors of PVT (p < 0.001 for all) in AP patients. Conclusion PVT in AP is associated with significantly higher risk of death, AKI, shock, and need for mechanical ventilation. Chronic and alcoholic pancreatitis is associated with higher risk of PVT in AP.


  • Correction to: Trends and risk factors for 30‑day readmissions in patients with acute cholangitis: analysis from the national readmission database

    by Malav P. Parikh, Rajat Garg, Vibhu Chittajallu, Niyati Gupta, Shashank Sarvepalli, Rocio Lopez, Prashanthi N. Thota, Hassan Siddiki, Amit Bhatt, Prabhleen Chahal, et al.


  • EUS and secretin endoscopic pancreatic function test predict evolution to overt structural changes of chronic pancreatitis in patients with nondiagnostic baseline imaging

    by Tyler Stevens, Marc Monachese, PeterJ Lee, Kevin Harris, Sunguk Jang, Amit Bhatt, Prabhleen Chahal, Rocio Lopez

    Y of EUS and ePFT to predict the eventual development of overt chronic pancreatitis (CP) changes on computed tomography/magnetic resonance cholangiopancreatography (CT/MRCP). The aim of the study was to determine the ability of EUS and ePFT to predict disease progression in patients with suspected MCCP who had nondiagnostic baseline imaging. Methods: A retrospective cohort study was conducted. Patients who underwent EUS and ePFT for suspected CP and who had nondiagnostic CT or MRCP were included. Patients without repeat imaging performed more than 1 year after their initial EUS/ePFT were excluded. Imaging was considered diagnostic if calcifications, main duct dilation (Cambridge Class III/IV), or severe atrophy were identified. Patients lost to follow-up were contacted to complete a survey documenting current symptoms and whether patients progressed to CP based on imaging. Univariable and multivariable analyses were performed using Cox regression. Results: Two hundred and thirty patients who underwent EUS/ePFT for suspected MCCP were identified between 2006 and 2012. Of these, 90 had a non-diagnostic baseline imaging test and subsequently a follow-up imaging test greater than 1 year later.These 90 patients constituted our study population. During a mean follow-up of 7 years, 19 (21%) patients developed CP by histology and imaging. Abnormal ePFT (peak bicarbonate <80 mmol) was a significant predictor of progression (hazard ratio [HR]: 4.7, confidence interval [CI]: 1.8, 12.4). Likewise, EUS Rosemont classification “suggestive/most-consistent” was a significant predictor of progression (HR: 7.3, CI: 2.4, 22.1). Conclusions: In patients with abdominal pain of suspected pancreatic origin and with nondiagnostic cross-sectional imaging, EUS and ePFT results predict the development of classic CP structural changes over time. These results support EUS and ePFT as effective tools for predicting progression of minimal change to overt CP....


  • Introduction and Validation of a Novel Acute Pancreatitis Digital Tool

    by Pedram Paragomi, Daniel M. Spagnolo, Cameron R. Breze, Amir Gougol, Rupjyoti Talukdar, Rakesh Kochhar, Mahesh Kumar Goenka, Aiste Gulla, Jose A. Gonzalez, Vikesh K. Md Singh, et al.

    Objectives: Acute pancreatitis (AP) is a sudden onset, rapidly evolving inflammatory response with systemic inflammation and multiorgan failure (MOF) in a subset of patients. New highly accurate clinical decision support tools are needed to allow local doctors to provide expert care. Methods: Ariel Dynamic Acute Pancreatitis Tracker (ADAPT) is a digital tool to guide physicians in ordering standard tests, evaluate test results and model progression using available data, propose emergent therapies. The accuracy of the severity score calculators was tested using 2 prospectively ascertained Acute Pancreatitis Patient Registry to Examine Novel Therapies in Clinical Experience cohorts (pilot University of Pittsburgh Medical Center, n = 163; international, n = 1544). Results: The ADAPT and post hoc expert-calculated AP severity scores were 100% concordant in both pilot and international cohorts. High-risk criteria of all 4 severity scores at admission were associated with moderately-severe or severe AP and MOF (both P < 0.0001) and prediction of no MOF was 97.8% to 98.9%. The positive predictive value for MOF was 7.5% to 14.9%. Conclusions: The ADAPT tool showed 100% accuracy with AP predictive metrics. Prospective evaluation of ADAPT features is needed to determine if additional data can accurately predict and mitigate severe AP and MOF.


  • The Risk of Vitamin D Deficiency, Osteoporosis, and Fractures in Acute Pancreatitis

    by Mohannad Abou Saleh, Motasem Alkhayyat, Emad Mansoor, George Khoudari, C. Roberto Simons-Linares, John Vargo, Prabhleen Chahal, Tyler Stevens

    Objectives: A few past studies have found increased utilization of 25-hydroxyvitamin D and prevalence of osteoporosis in acute pancreatitis (AP). Our aim was to obtain a survey of bone diseases after a sentinel episode of AP. Methods: A database (Explorys), an aggregate of electronic health record from 26 integrated United States healthcare systems, was queried. A cohort of patients with a Systematized Nomenclature of Medicine—Clinical Terms diagnosis of AP between 2014 and 2019, after excluding patients with selected medical conditions and medications that are associated with poor bone health, was identified. The prevalence of new diagnoses of vitamin D deficiency (VDD), osteoporosis, and fractures in the study cohort was evaluated. Age-, race-, and sex-based distributions and risk factors were determined through univariate and multivariate analyses. Results: Of the 36,087,380 individuals in the database, we identified 256,580 (0.71%) with AP. In multivariate analysis, patients with AP were more likely to develop VDD (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.24–1.26; P < 0.0001), osteoporosis (OR, 1.89; CI, 1.81–1.85; P < 0.0001), and fractures (OR, 1.58; 95% CI, 1.57–1.59; P < 0.0001). Conclusions: Acute pancreatitis was associated with increased risk of VDD, osteoporosis, and fractures.


  • Trends and risk factors for 30-day readmissions in patients with acute cholangitis: analysis from the national readmission database

    by Malav P. Parikh, Rajat Garg, Vibhu Chittajallu, Niyati Gupta, Shashank Sarvepalli, Rocio Lopez, Prashanthi N. Thota, Hassan Siddiki, Amit Bhatt, Prabhleen Chahal, et al.

    Introduction Acute cholangitis (AC) can be associated with significant mortality and high risk of readmissions, if not managed promptly. We used national readmission database (NRD) to identify trends and risk factors associated with 30-day readmissions in patients with AC. Methods We conducted a retrospective cohort study of adult patients admitted with AC from 2010–2014 and Q1-Q3 of 2015 by extracting data from NRD. Initial admission with a primary diagnosis of acute cholangitis (ICD-9 code: 576.1) was considered as the index admission and any admission after index admission was considered a readmission regardless of the primary diagnosis. Multivariable regression analyses were performed to assess the association. Results From 52,906 AC index admissions, overall 30-day readmission rate was 21.48% without significant differences in the readmission rates across the study period. There was significant increase in the overall hospital charges for readmissions, while a significant reduction in the death rate was observed during the first readmission. Recurrent cholangitis (14%), septicemia (6.4%), and mechanical complication of bile duct prosthesis (3%) were the most common reasons for readmissions. The risk of readmission was significantly higher in patients with pancreatic neoplasm (OR 1.6, 95% CI 1.4–1.8), those who underwent percutaneous biliary procedures (OR 1.4, 95% CI 1.2–1.6), and who had an acute respiratory failure (OR 1.2, 95% CI 1.0–1.15). Other factors contributing to increased risk of readmissions included patients with Charleston comorbidity index > 3, diabetes, and length of stay > 3 days. Readmission risk was significantly lower in patients who underwent ERCP (OR 0.80, 95% CI 0.73–0.88) or cholecystectomy (OR 0.54, 95% CI 0.43–0.69). Conclusions AC is associated with a high 30-day readmission rate of over 21%. Patients with malignant biliary obstruction, increased comorbidities, and those who undergo percutaneous drainage rather than ERCP seem to be at the highest risk.


  • Association of Statins With Decreased Acute Pancreatitis Severity

    by Peter J. Lee, Kunjam Modha, Tiffany Chua, Amitabh Chak, Daniel Jang, Rocio Lopez, Amir Gougol, Georgios I. Papachristou, Tyler Stevens

    Statins possess anti-inflammatory properties and have a protective effect in certain inflammatory conditions; however, their effect on the natural history of pancreatitis is unknown. The aim of this study is to assess the effect of statin exposure on the severity of pancreatitis and incidence of organ failure using a propensity-matched approach. A historical cohort study was conducted of adult patients with acute pancreatitis (AP) admitted in the Cleveland Clinic Health System between 2007 and 2014. All medication, clinical, and outcomes data were extracted from the electronic medical record. Factors that influence statin use were included in a propensity model to minimize selection bias. Patients on and off statins were matched (1:1) based on the propensity score to simulate a randomized controlled trial. Measured outcomes included pancreatitis severity (Revised Atlanta Classification), incidence of multisystem organ failure (MSOF), new MSOF, acute necrosis, and death. Additional surrogate markers of severity included hospital length of stay, Bedside Index of Severity of Acute Pancreatitis (BISAP), and presence of SIRS. A total of 110 subjects taking a statin at admission were matched with 210 subjects not on a statin. Known baseline factors that may influence statin use and severity of pancreatitis were evenly matched between the 2 groups. Patients on a statin were less likely to develop MSOF, severe AP and necrosis. Although less in-hospital death occurred in the statin group when compared to nonusers, the difference was not statistically significant (2% vs. 4%; P=0.38). Statin use is associated with decreased severity of AP observed as reduction in both overall MSOF incidence and new MSOF. Prospective randomized controlled trials are needed to determine the efficacy of statin drugs in the treatment of AP.


  • Open Access

    Autoimmunity in Autologous Islet Transplantation

    by Khawla F. Ali, Vicente T. San Martin, Tyler Stevens, R. Matthew Walsh, Rita Bottino, Massimo Trucco, Betul Hatipoglu

    Total pancreatectomy (TP) is increasingly being utilized for definitive treatment in patients with debilitating chronic pancreatitis (CP). In an effort to prevent surgical diabetes, the procedure can be performed in conjunction with transplantation of islets of Langerhans recovered from the patients’ own resected pancreas (autologous islet transplantation, AIT). Given that patients undergoing TP and AIT are traditionally assumed not to be at risk for the development of beta-cell autoimmunity, it is possible that the presence of autoimmune islet graft failure has been overlooked and underreported in this patient population. Herein, we describe two cases who underwent TP and AIT and later developed new-onset beta-cell autoimmunity (as evidenced by de novo glutamic acid decarboxylase antibody positivity), accompanied by complete insulin-dependent states. These cases emphasize the need for considering a possible autoimmune phenomenon in the workup of TP and AIT patients who manifest with unexpected and rapid deterioration in their glycemic control.